Biological characterization and selection criteria of adjuvant chemotherapy for early breast cancer: experience from the Italian observational NEMESI study

Matteo Clavarezza, Giorgio Mustacchi, Andrea Casadei Gardini, Lucia Del Mastro, Andrea De Matteis, Ferdinando Riccardi, Vincenzo Adamo, Enrico Aitini, Domenico Amoroso, Paolo Marchetti, Stefania Gori, Francesco Carrozza, Evaristo Maiello, Francesco Giotta, Davide Dondi, Marco Venturini, Matteo Clavarezza, Giorgio Mustacchi, Andrea Casadei Gardini, Lucia Del Mastro, Andrea De Matteis, Ferdinando Riccardi, Vincenzo Adamo, Enrico Aitini, Domenico Amoroso, Paolo Marchetti, Stefania Gori, Francesco Carrozza, Evaristo Maiello, Francesco Giotta, Davide Dondi, Marco Venturini

Abstract

Background: International treatment guidelines recommend administration of adjuvant chemotherapy in early breast cancer based on clinical, prognostic and predictive parameters.

Methods: An observational study (NEMESI) was conducted in 63 Italian oncology centres in patients with early breast cancer. Age, performance status, concomitant disease, menopausal status, histology, tumor dimension (pT), axillary lymph node status (pN), grading (G), estrogen and progesterone receptor (ER and PgR), proliferative index (ki67 or MIB-1), human epidermal growth factor receptor 2 (HER2) and type of adjuvant treatment were recorded. The primary objective of the study was to define parameters influencing the decision to prescribe adjuvant chemotherapy and the type of chemotherapy.

Results: Data for 1894 patients were available. 69.0% postmenopausal, 67.0% pT1, 22.3% pTmic/pT1a/pT1b, 61.0% pN0, 48.7% luminal A, 18.1% luminal B, 16.1% HER2 positive, 8.7% triple negative, 8.4% unknown. 57.8% received adjuvant chemotherapy: 38.1% of luminal A, 67.3% luminal B, 88.2% HER2-positive, 97.6% triple negative. Regimens administered: 9.1% CMF-like, 48.8% anthracyclines, 38.4% anthracyclines plus taxanes, 3.7% taxanes alone. Increasing pT/pN and, marginally, HER2-positive were associated with the prescription of anthracyclines plus taxanes. Suboptimal schedules (CMF-like or AC/EC or FEC-75) were prescribed in 37.3% receiving chemotherapy, even in HER2-positive and triple negative disease (36.5% and 34.0%, respectively).

Conclusions: This study showed an overprescription of adjuvant chemotherapy for early breast cancer, particularly referred to luminal A. pT, pN and, marginally, HER2 were the principal determinants for the choice of chemotherapy type. Suboptimal chemotherapy regimens were adopted in at least one third of HER2-positive and triple negative.

References

    1. The Nordcan Project. 2012. . Last update: 8 March.
    1. SEER, Surveillance Epidemiology and End Results. 2011. . Last update: November 10.
    1. Cancer Research UK. 2011. Last update: July 18.
    1. Ravdin PM, Cronin KA, Howlader N, Berg CD, Chebowski RT, Feuer EJ, Edwards BK, Berry DA. The decrease in breast-cancer incidence in 2003 in the United States. N Engl J Med. 2007;356:1670–1674. doi: 10.1056/NEJMsr070105.
    1. Rossouw JE, Anderson GL, Prentice RL, LaCroix AZ, Kooperberg C, Stefanick ML, Jackson RD, Beresford SA, Howard BV, Johnson KC, Kotchen JM, Ockene J. Writing Group for the Women's Health Initiative Investigators: Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women’s Health Initiative randomized controlled trial. JAMA. 2002;288:321–333. doi: 10.1001/jama.288.3.321.
    1. Crocetti E, Buzzoni C, Falcini F, Cortesi L, De Lisi V, Ferretti S, Tumino R, Russo A, Paci E. Disentangling the roles of mammographic screening and HRT in recent breast cancer trends in Italy by analyses based on calendar and time screening activation. Breast J. 2010;16:350–355.
    1. Buiatti E, Barchielli A, Bartolacci S, Bucchi L, De LV, Federico M, Ferretti S, Paci E, Vettorazzi M, Zanetti R. SCREENREG Working Group. Stage-specific incidence of breast cancer before the beginning of organized screening programs in Italy. Cancer Causes Control. 2002;13:65–71. doi: 10.1023/A:1013950821981.
    1. Paci E, Coviello E, Miccinesi G, Puliti D, Cortesi L, De Lisi V, Ferretti S, Mangone L, Perlangeli V, Ponti A, Ravaioli A, de' Bianchi PS, Segnan N, Stracci F, Tumino R, Zarcone M, Zorzi M, Zappa M. IMPACT Working Group. Evaluation of service mammography screening impact in Italy. The contribution of hazard analysis. Eur J Cancer. 2008;44:858–865. doi: 10.1016/j.ejca.2008.02.026.
    1. AIRTUM. I numeri del cancro in Italia. Intermedia Editore; 2011.
    1. Puliti D, Miccinesi G, Collina N, Puliti D, Miccinesi G, Collina N, De Lisi V, Federico M, Ferretti S, Finarelli AC, Foca F, Mangone L, Naldoni C, Petrella M, Ponti A, Segnan N, Sigona A, Zarcone M, Zorzi M, Zappa M, Paci E. IMPACT Working Group. Effectiveness of service screening: a case–control study to access breast cancer mortality reduction. Br J Cancer. 2008;99:423–427. doi: 10.1038/sj.bjc.6604532.
    1. Berry DA, Cronin KA, Plevritis SK, Fryback DG, Clarke L, Zelen M, Mandelblatt JS, Yakovlev AY, Habbema JD, Feuer EJ. Cancer Intervention and Surveillance Modeling Network (CISNET) Collaborators. Effect of screening and adjuvant therapy on mortality from breast cancer. N Engl J Med. 2005;353:1784–1792. doi: 10.1056/NEJMoa050518.
    1. National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology. Breast cancer; 2012. Version 1.2012.: 2012. Retrieved March 18.
    1. National Cancer Institute. Breast Cancer Treatment. 2012. PDQ. 2012. Retrieved March 18.
    1. Goldhirsch A, Wood WC, Coates AS, Gelber RD, Thurlimann B, Senn HJ. Panel Members: Strategies for subtypes-dealing with the diversity of breast cancer: highlights of the St. Gallen international expert consensus on the primary therapy of early breast cancer 2011. Ann Oncol. 2011;22:1736–1747. doi: 10.1093/annonc/mdr304.
    1. Associazione Italiana di Oncologia Medica (AIOM) Il Libro Bianco dell’Oncologia Italiana. third. 2006. [Italian]
    1. Greene FL, Page DL, Fleming ID. AJCC Cancer Staging Manual. 6. New York: Springer; 2002.
    1. Cazzaniga ME, Mustacchi G, Pronzato P, De Matteis A, Di Costanzo F, Floriani I. NORA Study Group. Adjuvant systemic treatment of early breast cancer: the NORA study. Ann Oncol. 2006;17:1386–1392. doi: 10.1093/annonc/mdl132.
    1. Cheang MC, Chia SK, Voduc D, Gao D, Leung S, Snider J, Watson M, Davies S, Bernard PS, Parker JS, Perou CM, Ellis MJ, Nielsen TO. Ki67 index, HER2 status and prognosis of patients with luminal B breast cancer. J Natl Cancer Inst. 2009;101:736–750. doi: 10.1093/jnci/djp082.
    1. Gori S, Clavarezza M, Siena S, Foglietta J, Tarenzi E, Giordano M, Molino A, Graiff C, Fusco V, Alabiso O, Baldini E, Gamucci T, Altavilla G, Dondi D, Venturini M. Adjuvant chemotherapy of pT1a and pT1b breast carcinoma: results from the NEMESI study. BMC Cancer. 2012;12:158. doi: 10.1186/1471-2407-12-158.
    1. Muss HB, Berry DA, Cirrincione CT, Theodoulou M, Mauer AM, Kornblith AB, Partridge AH, Dressler LG, Cohen HJ, Becker HP, Kartchescke PA, Wheeler JD, Perez EA, Wolff AC, Gralow JR, Burstein HJ, Mahmood AA, Magrinat G, Parker BA, Hart RD, Grenier D, Norton L, Hudis CA. Winer EPfor the CALGB Investigators. Adjuvant chemotherapy in older women with early-stage breast cancer. N Eng J Med. 2009;360:2055–2065. doi: 10.1056/NEJMoa0810266.
    1. Gennari A, Sormani MP, Pronzato P, Puntoni M, Colozza M, Pfeffer U, Bruzzi P. HER2 status and efficacy of adjuvant anthracyclines in early breast cancer: a pooled analysis of randomized trials. J Natl Cancer Inst. 2008;100:14–20. doi: 10.1093/jnci/djm252.
    1. De Laurentiis M, Cancello G. D Agostino D, Giuliano M, Giordano A, Montagna E, Lauria R, Forestieri V, Esposito A, Silvestro L, Pennacchio R, Criscitiello C, Montanino A, Limite G, Bianco AR, De Placido S: Taxane-based combinations as adjuvant chemotherapy of early breast cancer: a meta-analysis of randomized trials. J Clin Oncol. 2008;26:44–53. doi: 10.1200/JCO.2007.11.3787.
    1. Early Breast Cancer Trialists’ Collaborative Group. Comparison between different polychemotherapy regimens for early breast cancer: meta-analyses of long-term outcome among 100000 women in 123 randomized trials. Lancet. 2012;379:432–444.

Source: PubMed

Sponsoren und Mitarbeiter

Krankheiten

Drogeninterventionen

3
Abonnieren